Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Sign Up to like & getrecommendations! Published in 2022 at "Letters in applied microbiology"
DOI: 10.1111/lam.13664
Abstract: Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects… read more here.
Keywords: clostridium clostridioides; narrow spectrum; treatment; cdi ... See more keywords